ライフサイエンスコーパス: streptozotocin

1 matched type 1 diabetic rats (T1D) (60 mg/kg streptozotocin).

2 ed in rats via an intravascular injection of streptozotocin.

3 were rendered equally diabetic with low-dose streptozotocin.

4 T1D was initiated with streptozotocin.

5 ellitus was induced in male FVB/N mice using streptozotocin.

6 e graft loss, the animals were injected with streptozotocin.

7 HG was induced by consecutive injection of streptozotocin.

8 sculature and increased after treatment with streptozotocin.

9 ing Hes3 exhibited increased islet damage by streptozotocin.

10 ld male Wistar rats by injection of 65 mg/kg streptozotocin.

11 survival in response to the beta cell toxin streptozotocin.

12 Male Sprague-Dawley rats were injected with streptozotocin (30-45 mg/kg) or citrate vehicle.

13 as fat diet for 8 weeks before administering streptozotocin, 30 mg/kg body weight (T2D), and compared

14 (n = 8), after induction of type 1 diabetes (streptozotocin [50 mg/kg] intraperitoneally, 5 d), and a

15 7Bl/6J mice by intraperitoneal injections of streptozotocin (60 mg/kg).

16 A high-fat diet and low-dose streptozotocin administration were used to induce a type

17 rosis factor alpha (TNF-alpha) 4 weeks after streptozotocin administration, the retina of REDD1 knock

18 A diabetic state was induced by streptozotocin administration.

19 ice were injected with a single high dose of streptozotocin and 3 weeks thereafter used as oocyte don

20 ar hypertrophy were each blunted in EP1(-/-) streptozotocin and OVE26 cohorts compared with wild-type

21 knockout mice (EP1(-/-)) diabetic using the streptozotocin and OVE26 models.

22 rhesus macaques were rendered diabetic with streptozotocin and underwent islet allotransplantation.

23 tion, survival and beta-cell mass in type 1 (streptozotocin) and type 2 (obese Lepr(db/db)) diabetic

24 myocyte-specific overexpression of GCH1 with streptozotocin, and control animals were given citrate b

25 eficient diet, mice on a high-fat diet given streptozotocin, and mice with disruption of Pten in hepa

26 iabetes was induced) were made diabetic with streptozotocin, and some were given Ret-NH2 once per wee

27 The same mice given low doses of streptozotocin are a model of type 2 diabetes (T2D), dev

28 group, such as the bacterial natural product streptozotocin, are prominent carcinogens(1,2) and impor

29 iple time points after diabetes induction by streptozotocin as assessed by protein levels of microtub

30 nF, a metalloenzyme from the biosynthesis of streptozotocin, catalyses an oxidative rearrangement of

31 Treatment of TRPC6-deficient mice with streptozotocin caused severe reduction of cardiac contra

32 -transgenic (Ntg) and tau-knockout mice with streptozotocin, causing type 1 diabetes-like disease (T1

33 rved a pronounced drop in graft volume after streptozotocin challenge as assessed by MRI.

34 h early type 2 DN and in three mouse models (streptozotocin DBA/2, C57BLKS db/db, and eNOS-deficient

35 In streptozotocin diabetic mice, TRIB3 MOE exacerbated, whe

36 re able to normalize blood glucose levels in streptozotocin diabetic NOD/SCID mice.

37 ural tissues (sciatic nerve, spinal cord) of streptozotocin diabetic rats and mice.

38 Streptozotocin diabetic rats treated daily with heparin

39 livers of fasted as well as in high-fat-diet-streptozotocin diabetic rats, in which CREB is constitut

40 nd spinal cord oxidative-nitrative stress in streptozotocin diabetic rats.

41 ning hyperglycemia and hypercholesterolemia (streptozotocin diabetic, apoE-deficient mice), renal STA

42 r treatment with either vehicle (control) or streptozotocin (diabetic).

43 ia (DRG), and the trigeminal ganglia (TG) of streptozotocin-diabetic and healthy control rats.

44 .p.) effectively suppressed BRB breakdown in streptozotocin-diabetic Brown Norway rats.

45 After diabetes, streptozotocin-diabetic mice with heterozygous ATGL defi

46 ients and in aorta and carotid arteries from streptozotocin-diabetic versus nondiabetic C57BL/6 mice.

47 protein (CHOP)(-/-) mice made diabetic with streptozotocin displayed less severe sciatic nerve oxida

48 er impairment in glucose tolerance following streptozotocin exposure than WT mice, whereas Alox15 (-/

49 er, NHERF2, which were down-regulated in the streptozotocin group.

50 ard diabetes mouse model (high-fat diet plus streptozotocin [HFD/STZ]) to induce a mild increase in b

51 with streptozotocin, or both in combination (streptozotocin/HFD).

52 ved hyperglycemia and glucose intolerance in streptozotocin, high-fat diet-fed, and db/db diabetic mi

53 ta and hepatocellular carcinogenesis using a streptozotocin-high fat diet (STZ-HFD) induced nonalcoho

54 diabetic patients and diabetic mouse models (streptozotocin/high-fat diet-induced and db/db mice), mi

55 on) and intracerebroventricular injection of streptozotocin (ICVI-STZ).

56 DM was induced with 50 mg/kg intraperitoneal streptozotocin in 56 male Wistar rats.

57 2 diabetes mellitus was induced by low-dose streptozotocin in guinea pigs rendered glucose intoleran

58 We injected streptozotocin in male Sprague Dawley rats and treated t

59 As such, we induced hyperglycemia with streptozotocin in mice with monoallelic Nampt deletion f

60 reatment with the pancreatic beta-cell toxin streptozotocin induced hyperglycemia and raised plasma g

61 let cells to reverse hyperglycemia in murine streptozotocin induced- or non-obese diabetic mouse mode

62 icant, progressive inner retinal thinning in streptozotocin-induced "type 1" and B6.BKS(D)-Lepr(db)/J

63 rmed our in vitro findings using the in vivo streptozotocin-induced (STZ) diabetic rat model and ex-v

64 itoneal glucose tolerance tests in mice with streptozotocin-induced (type 1) diabetes and in a non-ge

65 otransplantation under the kidney capsule of streptozotocin-induced 8- to 10-week-old male athymic nu

66 injection of BTP2 exacerbates albuminuria in streptozotocin-induced and Akita diabetic mice.

67 ype 1 diabetic mice in two different models (streptozotocin-induced and Akita).

68 l and Western blot studies were performed in streptozotocin-induced and control Sprague-Dawley female

69 ith increased O2(*-) production in aortas of streptozotocin-induced and genetically induced Ins2(Akit

70 ndependent animal models of diabetes: db/db, streptozotocin-induced and mice fed a high-fat diet.

71 Experimental diabetes (streptozotocin-induced and ob/ob mice) or chemical sympa

72 s associated with improved glucose levels in streptozotocin-induced beta-cell destruction and high-fa

73 Ralpha signaling were further compromised by streptozotocin-induced diabetes and ameliorated by feedi

74 ofiling of glomeruli isolated from rats with streptozotocin-induced diabetes and controls.

75 diabetes, examining the kidneys of rats with streptozotocin-induced diabetes and kidney cells exposed

76 ing VDR in beta-cells were protected against streptozotocin-induced diabetes and presented a preserve

77 % (P < 0.01) in apoE knockout (KO) mice with streptozotocin-induced diabetes consuming an atherogenic

78 Subjecting Nox5(pod+) mice to streptozotocin-induced diabetes further exacerbated thes

79 We found that streptozotocin-induced diabetes in mice skewed hematopoi

80 onsecutive days in an in vivo mouse model of streptozotocin-induced diabetes inhibited the loss of ti

81 For this purpose, rats with streptozotocin-induced diabetes mellitus (STZ-DM) were t

82 were reduced in the myocardium of mice with streptozotocin-induced diabetes mellitus as compared to

83 Streptozotocin-induced diabetes mellitus in animals lead

84 Streptozotocin-induced diabetes mellitus in mice was stu

85 Using the streptozotocin-induced diabetes mouse model, we administ

86 the corneal clock, we studied the effects of streptozotocin-induced diabetes on the mitosis of epithe

87 p53inp2 exhibited enhanced muscle wasting in streptozotocin-induced diabetes that was dependent on au

88 comorbid diabetes (aging, high-fat diet, and streptozotocin-induced diabetes) had heightened lung ACE

89 c-Rel-deficient mice are resistant to streptozotocin-induced diabetes, a drug-induced model of

90 GR5 dual agonist INT-767 to DBA/2J mice with streptozotocin-induced diabetes, db/db mice with type 2

91 (AC) ), under three experimental conditions (streptozotocin-induced diabetes, during normal aging, an

92 In a model of streptozotocin-induced diabetes, miR-146a(-/-) mice show

93 were able to protect recipient mice against streptozotocin-induced diabetes, restoring a physiologic

94 Using a rat model with streptozotocin-induced diabetes, we measured the effects

95 in D (CypD)-deficient mice (Ppif (-/-)) with streptozotocin-induced diabetes, we observed an increase

96 c pancreata were transplanted into mice with streptozotocin-induced diabetes.

97 ects, and granulation tissues from mice with streptozotocin-induced diabetes.

98 SCHAD knockout (SCHADKO) mice into mice with streptozotocin-induced diabetes.

99 nal brush border membrane (BBM) of mice with streptozotocin-induced diabetes.

100 iferative islet cells and with resistance to streptozotocin-induced diabetes.

101 hyperglycemia and ex vivo, in a rat model of streptozotocin-induced diabetes.

102 not exacerbate retinal endothelial injury in streptozotocin-induced diabetes.

103 g were evaluated in C57BL/6J adult mice with streptozotocin-induced diabetes.

104 cible human Nox5 transgenic mouse exposed to streptozotocin-induced diabetes.

105 The study was performed in streptozotocin-induced diabetic (db/db) mice.

106 iabetes-prone BioBreeding/Worcester rats and streptozotocin-induced diabetic (STZ-D) rats and compare

107 n diabetic macrovascular and renal injury in streptozotocin-induced diabetic apolipoprotein E(-/-) mi

108 f combined hyperglycemia and hyperlipidemia (streptozotocin-induced diabetic apolipoprotein E-deficie

109 t diabetes-associated atherosclerosis in the streptozotocin-induced diabetic apolipoprotein E-knockou

110 Controls and streptozotocin-induced diabetic C57BL/6 mice were inject

111 Streptozotocin-induced diabetic C57BL/6N (H-2) mice were

112 in skeletal muscle is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy through a

113 xpression of EcSOD is sufficient to mitigate streptozotocin-induced diabetic cardiomyopathy.

114 a novel lens aldose reductase inhibitor in a streptozotocin-induced diabetic cataract model.

115 divided into normoglycemic (NG, n = 20) and streptozotocin-induced diabetic groups that were untreat

116 from mice subjected to prolonged fasting or streptozotocin-induced diabetic ketoacidosis.

117 The study was performed in streptozotocin-induced diabetic mice (C57BL/6).

118 5 islets were transplanted into the liver of streptozotocin-induced diabetic mice (H-2) via the porta

119 Retinal microvessels from streptozotocin-induced diabetic mice and human donors wi

120 Deprivation of insulin in streptozotocin-induced diabetic mice decreased mitochond

121 We show that insulin deficiency in streptozotocin-induced diabetic mice decreased mitochond

122 m CSCs cultured from the cardiac biopsies of streptozotocin-induced diabetic mice displayed impaired

123 Low-dose streptozotocin-induced diabetic mice exhibited increased

124 jected intraperitoneally in immune competent streptozotocin-induced diabetic mice for therapeutic eff

125 Streptozotocin-induced diabetic mice had reduced blood f

126 Control and streptozotocin-induced diabetic mice were therefore admi

127 In streptozotocin-induced diabetic mice, 1,25-VitD3 also pr

128 their capacity to regulate blood glucose in streptozotocin-induced diabetic mice, indicating that ad

129 In the retinas of streptozotocin-induced diabetic mice, retinal apoptosis

130 In streptozotocin-induced diabetic mice, TXNIP knockdown to

131 lopment of oxidative stress in the retina of streptozotocin-induced diabetic mice.

132 R-29a levels in primary renal glomeruli from streptozotocin-induced diabetic mice.

133 vely preblock exocrine GLP-1R in healthy and streptozotocin-induced diabetic mice.

134 e significantly increased in the duodenum of streptozotocin-induced diabetic mice.

135 ere transplanted under the kidney capsule of streptozotocin-induced diabetic mice; viability, functio

136 of data from aortic vessels in the low-dose streptozotocin-induced diabetic mouse model (10 animals)

137 In parallel, using streptozotocin-induced diabetic mouse model, we found th

138 suppression would lead to normoglycemia in a streptozotocin-induced diabetic mouse model.

139 dimensional imaging in vivo and in situ in a streptozotocin-induced diabetic mouse model.

140 ncomitant beta-cell survival and number in a streptozotocin-induced diabetic mouse model.

141 ere transplanted under the kidney capsule of streptozotocin-induced diabetic NM.

142 apy, tested in cutaneous wounds developed in streptozotocin-induced diabetic NOD/SCID mice.

143 Experiments using streptozotocin-induced diabetic Rab38 knockout and contr

144 functional roles of circulating MPs using a streptozotocin-induced diabetic rat model with well-char

145 that, by 4 weeks after diabetes onset in the streptozotocin-induced diabetic rat model, there is a la

146 s was also detected in serum and vitreous of streptozotocin-induced diabetic rats (STZ-rats) analyzed

147 Streptozotocin-induced diabetic rats (STZ-rats) were tre

148 retinal vascular leakage and leukostasis in streptozotocin-induced diabetic rats and in Akita mice.

149 Studies were conducted in streptozotocin-induced diabetic rats and in cultured ret

150 Streptozotocin-induced diabetic rats and mice were orall

151 gated whether early retinal abnormalities in streptozotocin-induced diabetic rats are alleviated by p

152 Ins2(Akita) diabetic mice and streptozotocin-induced diabetic rats exhibited marked re

153 n on oxidative stress and organ histology in streptozotocin-induced diabetic rats fed a high fat (HF)

154 for four days, and retinal microvessels from streptozotocin-induced diabetic rats in poor glycemia fo

155 Streptozotocin-induced diabetic rats showed decreased a-

156 ubcutaneously into nondiabetic (control) and streptozotocin-induced diabetic rats to elicit a granula

157 of the fabricated dressings was evaluated in streptozotocin-induced diabetic rats.

158 tein expression was increased in proteinuric streptozotocin-induced diabetic rats.

159 se 1 (LSD1) were measured in the retina from streptozotocin-induced diabetic rats.

160 with Keap1 was investigated in the retina of streptozotocin-induced diabetic rats.

161 Islet allograft survival was investigated in streptozotocin-induced diabetic recipient BALB/c (H-2d)

162 lted in reversion to normoglycemia in 50% of streptozotocin-induced diabetic recipients (n=12) compar

163 In streptozotocin-induced diabetic SCID/beige mice, the inj

164 Here, we show that in Streptozotocin-induced diabetic wild type mice, hypo-pho

165 in vitro podocyte culture experiments and a streptozotocin-induced DKD model in FHL2 gene-knockout m

166 In a rat model of streptozotocin-induced hyperglycemia, we found that endo

167 to four groups: 1) nondiabetic (NONDIAB), 2) streptozotocin-induced insulin deficiency (STZ), 3) STZ

168 ins significantly lower blood glucose in the streptozotocin-induced model of diabetes.

169 In a streptozotocin-induced model of T1D in mice, ML351 preve

170 Through testing streptozotocin-induced pancreatic islet disruption and f

171 Here, we employed a streptozotocin-induced rat model (STZ-DM) of uncontrolle

172 t effects of leptin replacement therapy in a streptozotocin-induced rat model of DKA.

173 Herein, streptozotocin-induced T1DM rats and age-matched non-dia

174 SNP administered for 3 weeks to mice with streptozotocin-induced type 1 diabetes ameliorated kidne

175 In a mouse model of streptozotocin-induced type 1 diabetes, (52)Mn(2+) uptak

176 In streptozotocin-induced type 1 diabetes, podocyte-specifi

177 We conducted studies in animals (streptozotocin-induced type 1 diabetic mice) and cellula

178 In streptozotocin-induced type 1 diabetic mice, there was a

179 ieu of vascular growth factors is altered in streptozotocin-induced type 1 diabetic mice, with decrea

180 port proof-of-concept in vivo efficacy in an streptozotocin-induced vascular leakage model (rat) and

181 were implanted under the scalp in diabetic (streptozotocin-induced) and control rats, which were sac

182 of HIPK2, was decreased in the glomeruli of streptozotocin injected diabetic mice.

183 on of p53 in the renal cortex of control and streptozotocin-injected diabetic mice.

184 We induced type 1 diabetes in rats by streptozotocin injection and demonstrated a substantial

185 nduced in FVB mice fed on a high-fat diet by streptozotocin injection followed by ligation of the lef

186 Streptozotocin injection in rats led to a progressive PP

187 t for 16 weeks, then either made diabetic by streptozotocin injection or kept normoglycemic.

188 After streptozotocin injection to induce diabetes, wild-type m

189 that, upon induction of diabetes type 1 via streptozotocin injection, Cyp4a14KO male mice developed

190 Ten weeks after streptozotocin injection, diabetic mice showed significa

191 ition of type 1 diabetes mellitus induced by streptozotocin injection.

192 ere subjected to diabetes mellitus either by streptozotocin injections (type 1 diabetes mellitus mode

193 lammatory cells and were made diabetic using streptozotocin injections.

194 y, autoimmunity, or diabetogenic agents like streptozotocin may confound understanding alloimmunity i

195 caused by diet-induced insulin resistance or streptozotocin-mediated beta-cell mass depletion, PKA ac

196 Diabetes was induced using the low-dose streptozotocin method.

197 n diabetic CMSCs and in the heart of HFD and streptozotocin mice eliciting, in HFD, DNA demethylation

198 ell mass and regeneration: multiple low-dose streptozotocin (MLDS) and partial pancreatectomy (Ppx).

199 tes in the T cell-mediated multiple low-dose streptozotocin (MLDS) model.

200 gated hyperglycemia in the multiple low-dose streptozotocin model of diabetes, demonstrating that eng

201 Second, in the streptozotocin model of hyperglycemia-induced renal inju

202 Using a streptozotocin mouse model of diabetic retinopathy, we r

203 In genetic (Akita) and pharmacological (streptozotocin) murine models of type 1 diabetes, cardia

204 fects of dietary flaxseed oil or fish oil on streptozotocin-nicotinamide induced diabetic rats were i

205 In addition, streptozotocin-nicotinamide-induced diabetic mice treate

206 f Tg-IGF2 mice with subdiabetogenic doses of streptozotocin or crossing these mice with a transgenic

207 xposed to high-fat diet (HFD), injected with streptozotocin, or both in combination (streptozotocin/H

208 However, when subjected to streptozotocin plus high-fat diet to induce islet inflam

209 Six weeks after streptozotocin premedication, Wistar male rats presentin

210 ce rendered hyperglycemic following low-dose streptozotocin prior to increasing cardiomyocyte glucose

211 tosis and preserves pancreatic beta-cells in streptozotocin-rendered hyperglycemic mice.

212 t pregestational diabetes in mice induced by streptozotocin significantly increased 4-hydroxynonenal

213 A single, intraperitoneal injection of streptozotocin (STZ) (35 mg/kg) resulted in hyperglycemi

214 d with a single intraperitoneal injection of streptozotocin (STZ) (n = 10); group 2 (G2): rats were n

215 yofilaments, restoring Ca(2+) sensitivity in streptozotocin (STZ) diabetic cardiac muscles.

216 tic mice induced by high fat diet (HFD) plus streptozotocin (STZ) in C57BL/6J mice for 13 weeks start

217 atic beta-cells were chemically destroyed by streptozotocin (STZ) in Gcgr(-/-):Glp-1r(-/-) mice and i

218 ned to two groups: diabetic group induced by streptozotocin (STZ) injection or normoglycemic controls

219 ignals were confirmed in diabetic mice after streptozotocin (STZ) injection.

220 of action in a mouse model of DPN induced by streptozotocin (STZ) injection.

221 Here, we used multiple low-dose (MLD) streptozotocin (STZ) injections and the NOD mouse model

222 thase (Nos3)-deficient mice by five low-dose streptozotocin (STZ) injections.

223 t week 14 all mice were rendered diabetic by streptozotocin (STZ) injections.

224 in K knockout mice were rendered diabetic by streptozotocin (STZ) injections.

225 Streptozotocin (STZ) is widely used as diabetogenic agen

226 is, and inflammation in the experimental rat streptozotocin (STZ) model of diabetic retinopathy (DR).

227 second model of type 1 DM, mice treated with streptozotocin (STZ) showed a similar increase in suscep

228 reased in platelets isolated from mice given streptozotocin (STZ) to induce T1DM in concert with indu

229 tion, adult male Wistar rats received either streptozotocin (STZ) to induce uDM (STZ-DM) or vehicle a

230 knockout (TLR4KO) mice were made diabetic by streptozotocin (STZ) treatment, and bladder contractile

231 Two groups of Wistar rats were injected with streptozotocin (STZ) two days after birth using 45 and 9

232 In response to multiple low-dose streptozotocin (STZ), hep-tg animals developed less seve

233 tes was employed involving administration of streptozotocin (STZ), which produces hypoinsulinemia in

234 retinal microvascular endothelial injury in streptozotocin (STZ)-diabetic rats fed a laboratory West

235 Normal Sprague-Dawley rats as well as RH or streptozotocin (STZ)-diabetic rats received bilateral VM

236 ced model of obesity and a nicotinamide (NA)-streptozotocin (STZ)-HFD-induced model of mild type 2 di

237 and insulin resistance and nicotinamide (NA)-streptozotocin (STZ)-HFD-induced type 2 diabetes.

238 of the PI 3-kinase/Akt pathway and increased streptozotocin (STZ)-induced apoptosis; conversely, over

239 lodeficiency of Klotho (KL(+/-)) exacerbated streptozotocin (STZ)-induced diabetes (a model of T1DM),

240 Four beagle dogs with streptozotocin (STZ)-induced diabetes and four healthy d

241 or 3 wk dramatically reduced the severity of streptozotocin (STZ)-induced diabetes in nonobese diabet

242 Streptozotocin (STZ)-induced diabetes is the most common

243 d alpha-cell voltage-gated ion channels in a streptozotocin (STZ)-induced diabetes model that lead to

244 tin dose-response study in C57Bl/6 mice with streptozotocin (STZ)-induced diabetes to determine a lep

245 d glucose and insulin tolerance in mice with streptozotocin (STZ)-induced diabetes, an insulin-defici

246 and HYAL1 knockout (KO) mice with or without streptozotocin (STZ)-induced diabetes.

247 9 would normalize cutaneous wound healing in streptozotocin (STZ)-induced diabetic (STZ-diabetic) mic

248 n, and suppressed atherosclerotic lesions in streptozotocin (STZ)-induced diabetic ApoE(-/-) mice.

249 stigated in vivo by administration of PP2 to streptozotocin (STZ)-induced diabetic DBA2/J mice.

250 and segmental glomerulosclerosis (FSGS) and streptozotocin (STZ)-induced diabetic glomerulosclerosis

251 ated restoration of functional beta-cells in streptozotocin (STZ)-induced diabetic mice.

252 early alterations within the bone marrow of streptozotocin (STZ)-induced diabetic rats following tre

253 radix puerariae, reduces diabetic injury in streptozotocin (STZ)-induced diabetic rodent models.

254 Age-matched control or streptozotocin (STZ)-induced diabetic, and db/db mice wi

255 ic backgrounds were protected from high-fat/ streptozotocin (STZ)-induced hyperglycemia that was acco

256 pment of glomerulopathy and albuminuria upon streptozotocin (STZ)-induced hyperglycemia.

257 In a rat model of streptozotocin (STZ)-induced T1D, GHRH receptor expressi

258 We show here that during streptozotocin (STZ)-induced T1D, the nucleotide-binding

259 adoptively transferred to multiple low-dose streptozotocin (STZ)-induced T1DM.

260 tosolic form of Trx) in the VMH of rats with streptozotocin (STZ)-induced type 1 diabetes.

261 in isolated heart mitochondria from Sham and streptozotocin (STZ)-induced type 1 diabetic (T1DM) guin

262 Experimental DR in streptozotocin (STZ)-injected rodents is described as an

263 Gcgr(-/-)) do not develop diabetes following streptozotocin (STZ)-mediated ablation of insulin-produc

264 three mouse models of diabetic nephropathy: streptozotocin (STZ)-treated, OVE26, and Akita mice.

265 e using repeated injections of a low dose of streptozotocin (STZ).

266 duced diabetes in these M-FoxO-TKO mice with streptozotocin (STZ).

267 lows: 1) non-ligated control (NL, n = 6); 2) streptozotocin (STZ, n = 8); 3) STZ and melatonin (STZ+M

268 Dahl Salt-Sensitive rats by an injection of streptozotocin (STZ-SS).

269 genitor cells using mouse models of chronic (streptozotocin [STZ]-induced diabetes) and acute (ischem

270 lating warhead of the pancreatic cancer drug streptozotocin (SZN) contains an N-nitrosourea moiety co

271 e of these pathways, rats were injected with streptozotocin to induce diabetes and implanted subcutan

272 f experimental diabetic nephropathy, we used streptozotocin to induce diabetes in wild-type C57BL/6 a

273 nsgenic (miR-133aTg) mice were injected with streptozotocin to induce diabetes.

274 Male C57BL/6 mice were injected streptozotocin to induce diabetes.

275 rat pancreatic islet cells transplanted into streptozotocin-treated diabetic C57BL/6 mice, islets pre

276 edly hypoglycemic range in overnight-fasted, streptozotocin-treated Gcgr(-/-) mice.

277 level also was observed in overnight-fasted, streptozotocin-treated ghrelin receptor-null mice that w

278 Streptozotocin-treated male Wistar rats were fed a chole

279 Streptozotocin-treated mice had increased pacemaker cell

280 Streptozotocin-treated mice showed increased levels of s

281 le for the cognitive decline observed in Ntg streptozotocin-treated mice.

282 nse were diminished in diabetic retinas from streptozotocin-treated mice.

283 Streptozotocin-treated MM-VV mice and WT mice infused wi

284 Consistent with findings in humans, streptozotocin-treated rats had lower brain glucose leve

285 Livers from streptozotocin-treated T1D rats demonstrated a significa

286 ogy in humans, we examined brain tissue from streptozotocin-treated type 1 diabetic adult male vervet

287 via p63/REDD1 pathway in skeletal muscle of Streptozotocin-treated wild type mice.

288 male mice developed worse renal disease than streptozotocin-treated wild-type mice, characterized by

289 rease fasting blood glucose at 30 mg/kg in a streptozotocin-treated, diet-induced obesity mouse pharm

290 fferent hyperglycemic diabetic mouse models: streptozotocin-treated, high-fat fed, and Ins2Akita.

291 In Myostatin(-/-) mice however, Streptozotocin treatment did not reduce Akt phosphorylat

292 atic insulin content after multiple low-dose streptozotocin treatment.

293 rved in Myostatin(-/-) muscle in response to Streptozotocin treatment.

294 TAT and suppression of TH in the heart after streptozotocin was administered.

295 Streptozotocin was used to induce DM and EP was induced

296 function (Sema3a(+)) mice made diabetic with streptozotocin, we demonstrate that sema3a is pathogenic

297 M1R-deficient mice made diabetic with streptozotocin were protected from physiological and str

298 In the streptozotocin-western diet model, therapeutic Ang-2 inh

299 n the methionine-choline deficient (MCD) and streptozotocin-western diet nonalcoholic fatty liver dis

300 ritoneal space of C57BL/6J mice treated with streptozotocin, which is an animal model for chemically